RT Journal Article
SR Electronic
T1 Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.23.20160317
DO 10.1101/2020.07.23.20160317
A1 Shixiong Hu
A1 Wei Wang
A1 Yan Wang
A1 Maria Litvinova
A1 Kaiwei Luo
A1 Lingshuang Ren
A1 Qianlai Sun
A1 Xinghui Chen
A1 Ge Zeng
A1 Jing Li
A1 Lu Liang
A1 Zhihong Deng
A1 Wen Zheng
A1 Mei Li
A1 Hao Yang
A1 Jinxin Guo
A1 Kai Wang
A1 Xinhua Chen
A1 Ziyan Liu
A1 Han Yan
A1 Huilin Shi
A1 Zhiyuan Chen
A1 Yonghong Zhou
A1 Kaiyuan Sun
A1 Alessandro Vespignani
A1 Cécile Viboud
A1 Lidong Gao
A1 Marco Ajelli
A1 Hongjie Yu
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.07.23.20160317.abstract
AB Several mechanisms driving SARS-CoV-2 transmission remain unclear. Based on individual records of 1,178 SARS-CoV-2 infectors and their 15,648 contacts in Hunan, China, we estimated key transmission parameters. The mean generation time was estimated to be 5.7 (median: 5.5, IQR: 4.5, 6.8) days, with infectiousness peaking 1.8 days before symptom onset, with 95% of transmission events occurring between 8.8 days before and 9.5 days after symptom onset. Most of transmission events occurred during the pre-symptomatic phase (59.2%). SARS-CoV-2 susceptibility to infection increases with age, while transmissibility is not significantly different between age groups and between symptomatic and asymptomatic individuals. Contacts in households and exposure to first-generation cases are associated with higher odds of transmission. Our findings support the hypothesis that children can effectively transmit SARS-CoV-2 and highlight how pre-symptomatic and asymptomatic transmission can hinder control efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2017ZX10103009-005, No. 2018ZX10713001-007, No. 2018ZX10201001-010), and Hunan Provincial Innovative Construction Special Fund: Emergency response to COVID-19 outbreak (No. 2020SK3012).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethic committee of the Hunan CDC with a waiver of informed consent due to a public health outbreak investigation (IRB No. 2020005).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-based data on 1,178 SARS-CoV-2 infected individuals and their 15,648 contacts identified by contact tracing monitoring over the period from January 13-April 02, 2020 were extracted from the notifiable infectious diseases reporting system in Hunan Province, China. Demographic characteristics, severity classification, exposure and travel history, and key clinical timelines were retrieved.All relevant data are within the manuscript and its Supporting Information files.